DNA vaccination against bcr-abl-positive cells in mice

被引:12
|
作者
Lucansky, Vincent [1 ]
Sobotkova, Eva [1 ]
Tachezy, Ruth [1 ]
Duskova, Martina [1 ]
Vonka, Vladimir [1 ]
机构
[1] Inst Hematol & Blood Transfus, Dept Expt Virol, CR-12820 Prague 2, Czech Republic
关键词
CML; bcr-abl-transformed mouse cells; DNA vaccines; CHRONIC MYELOGENOUS LEUKEMIA; LOADED DENDRITIC CELLS; IMATINIB MESYLATE; FUSION PEPTIDES; IMMUNOTHERAPY; ONCOGENE; IMMUNOGENICITY; TRANSFORMATION; MECHANISMS; DISEASE;
D O I
10.3892/ijo_00000408
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A series of DNA vaccines based on the bcr-abl fusion gene were developed and tested in mice. Two mouse (BALB/c) bcr-abl-transformed cell lines, B210 and 12131, which both expressed p210(bcr-abl) and were oncogenic for syngeneic animals but differed in some other respects, were used as a model system. In the first series of experiments, plasmids carrying either the complete bcr-abl fusion gene or a fragment thereof coding for a 25-amino acid-long junction zone (bcr-abl25aa) linked with genes coding for a variety of immunostimulatory factors were used as the DNA vaccines. A plasmid carrying the complete bcr-abl gene was capable of inducing protection against challenge with either B210 or 12B1 cells. However, the DNA vaccines based on the gene fragment coding for p25aa(bcr-abl) did not induce significant protection. To localize the immunizing epitopes on the p210(bcr-abl) protein, the whole fusion gene was split into nine overlapping fragments and these, individually or in various combinations, were used for immunization. Although none of the vaccines based on any single fragment provided potent protection, some combinations of these fragment-based vaccines were capable of eliciting protection comparable to that seen after immunization with the whole-gene vaccine. Surprisingly, a mixture of six fragment-vaccines was more immunogenic than the complete set of fragment DNA vaccines. To analyze this phenomenon, the three fragments missing from the hexavaccine were either individually or in various combinations mixed with the hexavaccine. The results obtained suggested that the product of the fragment coding for 197 amino acids forming the N-terminal of the BCR protein was involved in the decreased immunogenicity. However, further experiments are needed to clarify the point. Additional experiments revealed that all the important epitopes were located in the ABL portion of the p210(bcr-abl) protein. The livers, spleens and bone marrows of the successfully immunized animals were tested for the presence of bcr-abl-positive cells by RT-PCR. The results were negative, this suggesting that these animals were free of any residual disease.
引用
收藏
页码:941 / 951
页数:11
相关论文
共 50 条
  • [41] The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
    Deininger, MWN
    Goldman, JM
    Lydon, N
    Melo, JV
    BLOOD, 1997, 90 (09) : 3691 - 3698
  • [42] Combination treatment of imatinib-sensitive and -resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitors
    Radujkovic, Aleksandar
    Topaly, Julian
    Fruehauf, Stefan
    Zeller, W. Jens
    ANTICANCER RESEARCH, 2006, 26 (3A) : 2169 - 2177
  • [43] Suppression of Vascular Endothelial Growth Factor (VEGF) Expression by Targeting the Bcr-Abl Oncogene and Protein Tyrosine Kinase Activity in Bcr-Abl-positive Leukaemia Cells
    Li, L.
    Zhang, R.
    Fang, Z. Y.
    Chen, J. N.
    Zhu, Z. L.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2009, 37 (02) : 426 - 437
  • [44] PURGING OF PERIPHERAL-BLOOD STEM-CELLS YIELDS BCR-ABL-NEGATIVE AUTOGRAFTS IN PATIENTS WITH BCR-ABL-POSITIVE ACUTE LYMPHOBLASTIC-LEUKEMIA
    MARTIN, H
    ATTA, J
    BRUECHER, J
    ELSNER, S
    RODE, C
    WASSMANN, B
    HOELZER, D
    EXPERIMENTAL HEMATOLOGY, 1995, 23 (08) : 760 - 760
  • [45] Autologous bone marrow transplantation in patients with BCR-ABL-positive acute lymphoblastic leukemia
    Martin, H
    Atta, J
    Wassmann, B
    Bruecher, J
    Bergmann, L
    Salinger, R
    Stockschlader, M
    Bunjes, D
    Hoelzer, D
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 557 - 557
  • [46] Autologous BMT/PBSCT in patients with BCR-ABL-positive acute lymphoblastic leukemia.
    Martin, H
    Atta, J
    Fauth, F
    Ottmann, OG
    Ott, MG
    Wassmann, B
    Bergmann, L
    Knauf, W
    Gramatzki, M
    Zander, A
    Bunjes, D
    Arnold, R
    Hoelzer, D
    BONE MARROW TRANSPLANTATION, 1998, 21 : S2 - S2
  • [47] Functional p53 is required for effective execution of telomerase inhibition in BCR-ABL-positive CML cells
    Brassat, Ute
    Balabanov, Stefan
    Bali, Daniel
    Dierlamm, Judith
    Braig, Melanie
    Hartmann, Ulrike
    Sirma, Huseyin
    Gunes, Cagatay
    Wege, Henning
    Fehse, Boris
    Gontarewicz, Artur
    Dikomey, Ekkehard
    Borgmann, Kerstin
    Brumrnendorf, Tim H.
    EXPERIMENTAL HEMATOLOGY, 2011, 39 (01) : 66 - 76
  • [48] Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant BCR-ABL-positive cells
    Aleksandar Radujkovic
    Stefan Fruehauf
    W. Jens Zeller
    Anthony D. Ho
    Julian Topaly
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 255 - 264
  • [49] Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant BCR-ABL-positive cells
    Radujkovic, Aleksandar
    Fruehauf, Stefan
    Zeller, W. Jens
    Ho, Anthony D.
    Topaly, Julian
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (02) : 255 - 264
  • [50] Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells
    Tanaka, Ruriko
    Squires, Matthew S.
    Kimura, Shinya
    Yokota, Asumi
    Nagao, Rina
    Yamauchi, Takahiro
    Takeuchi, Miki
    Yao, Hisayuki
    Reule, Matthias
    Smyth, Tomoko
    Lyons, John F.
    Thompson, Neil T.
    Ashihara, Eishi
    Ottmann, Oliver G.
    Maekawa, Taira
    BLOOD, 2010, 116 (12) : 2089 - 2095